Similar Items: Investigating the relationship between plasma and intracellular concentrations of bedaquiline and its metabolite N-desmethyl bedaquiline (M2) in drug resistant-TB patients with and without HIV infection in South Africa
- Sodium, potassium adenosine triphosphatase as a potential target of the anti-tuberculosis agents, clofazimine and bedaquiline
- Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme
- Influence of previous tuberculosis treatment on time to culture conversion for patients receiving a bedaquiline-containing regimen at Sizwe Tropical Disease Hospital, South Africa
- Drug-drug interactions between antiretrovirals and bedaquiline
- Performance of host blood transcriptomic signatures for TB diagnosis and monitoring TB treatment
- Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC
Author: Wiesner, Lubbe
- Development and validation of selective and sensitive LC-MS/MS Methods for determination of para-aminosalicyclic acid and cycloserine/terizidone applicable to clinical studies for the treatment of tuberculosis
- Determination of total, unbound, and intracellular concentrations of the antiretroviral drugs Efavirenz, Lopinavir, and Ritonavir
- Screening rare filamentous actinobacteria for novel antimycobacterial compounds
- Simultaneous quantification of first-line anti-tuberculosis drugs and metabolites in human plasma
- A pharmacokinetic and antimalarial efficacy evaluation of pyridodibemequines and their metabolites
- Isolation and characterisation of antiplasmodial compounds from Xerophyta species and the bioavailability, metabolic and efficacy evaluation of 9-0-acetylhydnocarpin in a mouse model